Phase-III general clinical trial of Terbinafine(SF86-327)125mg tablets for nail condidiasis.
Author:
- Akira OgawaraAOAkira Ogawara
- 1 January 1994
- journal article
- Published by Western Japan Division of JDA in The Nishinihon Journal of Dermatology
- Vol. 56 (3) , 569-577
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Terbinafine in chronic paronychia and candida onychomycosisJournal of Dermatological Treatment, 1992
- Effect of squalene on the structure and function of fungal membranesJournal of Dermatological Treatment, 1992
- Selective action of allylamines and its therapeutic implicationsJournal of Dermatological Treatment, 1992
- Determination of terbinafine in nail samples during systemic treatment for onychomycosesBritish Journal of Dermatology, 1990
- Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymesJournal of Dermatological Treatment, 1990
- In vitro activity of terbinafineClinical and Experimental Dermatology, 1989
- Antifungal activity of the allylamine derivative terbinafine in vitroAntimicrobial Agents and Chemotherapy, 1987
- Inhibitory Effect of Antifungal Agents on Germ Tube Formation in Candida albicans. Hemmeffekt antifungaler Wirkstoffe auf die Keimschlauchbildung von Candida albicansMycoses, 1987
- In-vitro studies with SF 86–327, a new orally active allylamine derivativeMedical Mycology, 1985